Equities research analysts expect UroGen Pharma Ltd. (NASDAQ:URGN) to announce earnings of ($1.26) per share for the current quarter, Zacks Investment Research reports. Three analysts have provided estimates for UroGen Pharma’s earnings. The lowest EPS estimate is ($1.36) and the highest is ($1.10). UroGen Pharma reported earnings per share of ($1.31) during the same quarter last year, which indicates a positive year-over-year growth rate of 3.8%. The firm is scheduled to issue its next quarterly earnings results on Monday, November 8th.
According to Zacks, analysts expect that UroGen Pharma will report full year earnings of ($4.90) per share for the current year, with EPS estimates ranging from ($5.11) to ($4.52). For the next financial year, analysts anticipate that the business will report earnings of ($3.29) per share, with EPS estimates ranging from ($4.28) to ($1.61). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research analysts that cover UroGen Pharma.
UroGen Pharma (NASDAQ:URGN) last announced its quarterly earnings data on Wednesday, August 4th. The company reported ($1.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.10) by ($0.07). UroGen Pharma had a negative net margin of 349.05% and a negative return on equity of 127.56%. The business had revenue of $13.03 million during the quarter, compared to analyst estimates of $13.00 million.
URGN traded up $0.29 during trading on Friday, hitting $15.43. The company’s stock had a trading volume of 549 shares, compared to its average volume of 160,216. UroGen Pharma has a twelve month low of $14.19 and a twelve month high of $28.20. The stock’s fifty day moving average price is $15.73 and its 200-day moving average price is $17.39. The firm has a market capitalization of $322.49 million, a P/E ratio of -3.01 and a beta of 1.22.
A number of institutional investors and hedge funds have recently made changes to their positions in URGN. BNP Paribas Arbitrage SA raised its holdings in shares of UroGen Pharma by 17.4% in the 1st quarter. BNP Paribas Arbitrage SA now owns 4,439 shares of the company’s stock valued at $86,000 after acquiring an additional 657 shares in the last quarter. Public Employees Retirement System of Ohio raised its holdings in UroGen Pharma by 21.1% in the first quarter. Public Employees Retirement System of Ohio now owns 6,900 shares of the company’s stock worth $134,000 after purchasing an additional 1,200 shares in the last quarter. Algert Global LLC purchased a new stake in shares of UroGen Pharma in the 1st quarter worth about $227,000. State Board of Administration of Florida Retirement System bought a new stake in shares of UroGen Pharma in the 2nd quarter worth $239,000. Finally, Wells Fargo & Company MN raised its position in UroGen Pharma by 368.3% in the 2nd quarter. Wells Fargo & Company MN now owns 19,916 shares of the company’s stock worth $304,000 after buying an additional 15,663 shares during the last quarter.
About UroGen Pharma
UroGen Pharma Ltd. is a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases. It has developed RTGel reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs.
Further Reading: What is the Stochastic Momentum Index (SMI)?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for UroGen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UroGen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.